[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100645579":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":15,"locations":21,"responsibleParty":37,"collaborators":7,"id":39,"slug":40,"hasResults":41,"nctId":42,"briefTitle":43,"officialTitle":43,"acronym":44,"eligibilityCriteria":45,"healthyVolunteers":41,"sex":46,"minAge":47,"maxAge":7,"enrollmentInfo":48,"targetDuration":7,"studyType":51,"phases":7,"briefSummary":52,"conditions":53,"keywords":7,"overallStatus":24,"whyStopped":7,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":70},{"fullName":5,"class":6},"Cliniques universitaires Saint-Luc- Université Catholique de Louvain","OTHER",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":13},"DRUG","GLP-1 Receptor Agonists","Participants receive GLP-1 RA or GLP-1\u002FGIP dual agonists as part of their standard care for overweight or obesity",[14],"GLP-1\u002FGIP dual agonists",[16],{"name":17,"role":18,"phone":19,"phoneExt":7,"email":20},"Laura Orioli, MD, PhD","CONTACT","+32494507621","laura.orioli@saintluc.uclouvain.be",[22],{"facility":23,"status":24,"city":25,"state":7,"zip":26,"country":27,"countryCode":28,"cosmosGeoPoint":29,"geoPoint":34,"contacts":35},"Cliniques Universitaires Saint-Luc","RECRUITING","Woluwe-Saint-Pierre - Sint-Pieters-Woluwe","1150","Belgium","BE",{"type":30,"coordinates":31},"Point",[32,33],4.37067,50.85505,{"lat":33,"lon":32},[36],{"name":17,"role":18,"phone":19,"phoneExt":7,"email":20},{"type":38,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100645579","myokines-as-potential-biomarkers-and-drivers-of-sarcopenia-in-metabolic-and-endocrine-diseases-100645579",false,"NCT07703683","Myokines as Potential Biomarkers and Drivers of Sarcopenia in Metabolic and Endocrine Diseases","SARC-ENDO","Inclusion Criteria:\n\n* Metabolic or endocrine disease\n\nExclusion Criteria:\n\n* Known myopathy\n* Systemic steroid use (\\> 1 mg\u002Fkg hydrocortisone) or exogenous Cushing's syndrome\n* Psychological, family, sociological or geographical conditions that could potentially limit compliance with the study protocol\n* History of cancer within the five years prior to the study or Cushing's syndrome due to ACTH-secreting tumor","ALL","18 Years",{"count":49,"type":50},100,"ESTIMATED","OBSERVATIONAL","Prospective, observational, single-center, study evaluating the prevalence of sarcopenia \u002F sarcopenic obesity in individuals with metabolic and \u002F or endocrine diseases, as well as the potential role of myokines as biomarkers or drivers of sarcopenia \u002F sarcopenic obesity in this population.\n\n.",[54,55,56,57,58,59,60],"Diabetes","Obesity & Overweight","Cushing Syndrome","Metabolic Diseases","Endocrine Diseases","Sarcopenia","Sarcopenic Obesity","2026-07-10",{"date":63,"type":64},"2026-07-14","ACTUAL",{"date":66,"type":64},"2026-02-19",{"date":68,"type":50},"2056-12-31",{"name":5,"class":6},1]